Earnings ·
SOPHiA GENETICS SA reported unaudited financial results for the six months ended June 30, 2026
SOPHSOPHiA GENETICS SA
SOPHiA GENETICS SA reported unaudited financial results for the six months ended June 30, 2026. Revenue increased 25% to $45.0 million from $36.1 million in the prior year period, driven by a 19% rise in platform analysis volume and foreign exchange benefits. The company incurred a net loss of $41.7 million compared to $39.8 million previously, with operating expenses rising due to restructuring costs and legal fees related to ongoing patent litigation against Guardant Health. Cash and cash equivalents stood at $107.7 million as of June 30, 2026. The company operates in the healthcare technology industry, providing a cloud-native software platform for analyzing complex multimodal clinical data to support precision medicine.